Literature DB >> 12496389

Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity.

Wentao Gao1, Sanjay Kumar, Michael T Lotze, Charles Hanning, Paul D Robbins, Andrea Gambotto.   

Abstract

Recently, several novel members of the IL-1 family have been identified. The possible therapeutic utility and the underlying biologic role of these new members remain unclear. In the present study we analyzed the anti-tumor activity of human IL-1 homologue 4(IL-1H4; renamed IL-F7) by adenovirus-mediated gene transfer (AdIL-1H4) directly into murine tumors. In vitro expression analysis showed that IL-1H4 was a secretory protein. Treatment of an established MCA205 mouse fibrosarcoma by single intratumoral injection of AdIL-1H4 resulted in significant growth suppression. Furthermore, complete inhibition of tumor growth was observed following multiple injections of AdIL-1H4. The anti-tumor activity of IL-1H4 was abrogated in nude and SCID mice and in IL-12-, IFN-gamma-, or Fas ligand-deficient mice. In contrast, IL-1H4 was able to confer substantial anti-tumor effects in NKT-deficient mice. These results suggest that IL-1H4 could play an important role in the link between innate and adaptive immunity and may be useful for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496389     DOI: 10.4049/jimmunol.170.1.107

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer.

Authors:  Wei-qiang Wang; Dan Zhao; Yu-shan Zhou; Xiao-yu Hu; Zhi-na Sun; Gang Yu; Wan-tong Wu; Song Chen; Jiu-long Kuang; Guo-gang Xu; Zhong-chao Han; Bang-mao Wang; Jing-xian Yang; Xiao-ming Feng
Journal:  Acta Pharmacol Sin       Date:  2015-04       Impact factor: 6.150

2.  The variant interleukin 1f7 rs3811047 G>A was associated with a decreased risk of gastric cardiac adenocarcinoma in a Chinese Han population.

Authors:  Xu Wang; Jun Yin; Liang Zheng; Liming Wang; Yijun Shi; Weifeng Tang; Guowen Ding; Chao Liu; Ruiping Liu; Suocheng Chen; Haiyong Gu
Journal:  Tumour Biol       Date:  2013-12-21

3.  IL-37 mediates the antitumor activity in renal cell carcinoma.

Authors:  Yazhuo Jiang; Yili Wang; Liang Liang; Yang Gao; Juan Chen; Yi Sun; Yongyi Cheng; Yonggang Xu
Journal:  Med Oncol       Date:  2015-10-13       Impact factor: 3.064

4.  Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation.

Authors:  Y Li; M Zhao; C Guo; H Chu; W Li; X Chen; X Wang; Y Li; Y Jia; S Koussatidjoa; F Zhu; J Wang; X Wang; Q Wang; W Zhao; Y Shi; W Chen; L Zhang
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

5.  Plasma levels and expression of interleukin-37 in patients with immune thrombocytopenia.

Authors:  Feng Zhang; Xiao-Juan Zhu; Xiao-Jing Zhu; Yan-Xia Liu; Ting Yuan; Qing-Min Yao
Journal:  Exp Ther Med       Date:  2019-07-30       Impact factor: 2.447

6.  IL-10 and its related superfamily members IL-19 and IL-24 provide parallel/redundant immune-modulation in Loa loa infection.

Authors:  Alessandra Ricciardi; Thomas B Nutman
Journal:  J Infect Dis       Date:  2020-06-19       Impact factor: 5.226

7.  The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer.

Authors:  Vivi A Ding; Ziwen Zhu; Timothy A Steele; Mark R Wakefield; Huaping Xiao; Dean Balabanov; Yujiang Fang
Journal:  Med Oncol       Date:  2017-12-05       Impact factor: 3.064

8.  Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy.

Authors:  Lijuan Wang; Yanchun Quan; Yongfang Yue; Xueyuan Heng; Fengyuan Che
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 9.  IL-37: An anti-inflammatory cytokine with antitumor functions.

Authors:  Yu Mei; Haiyan Liu
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-22

Review 10.  The role of IL-37 in cancer.

Authors:  Vivi A Ding; Ziwen Zhu; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Med Oncol       Date:  2016-06-01       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.